[go: up one dir, main page]

FI970979A7 - Muokatut ihmisen C3-proteiinit - Google Patents

Muokatut ihmisen C3-proteiinit Download PDF

Info

Publication number
FI970979A7
FI970979A7 FI970979A FI970979A FI970979A7 FI 970979 A7 FI970979 A7 FI 970979A7 FI 970979 A FI970979 A FI 970979A FI 970979 A FI970979 A FI 970979A FI 970979 A7 FI970979 A7 FI 970979A7
Authority
FI
Finland
Prior art keywords
proteins
modified human
human
modified
Prior art date
Application number
FI970979A
Other languages
English (en)
Swedish (sv)
Other versions
FI970979A0 (fi
FI970979L (fi
Inventor
Richard Alexander Harrison
Timothy Charles Farries
Original Assignee
Imutran Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9418147A external-priority patent/GB9418147D0/en
Priority claimed from GBGB9509102.1A external-priority patent/GB9509102D0/en
Application filed by Imutran Ltd filed Critical Imutran Ltd
Publication of FI970979A7 publication Critical patent/FI970979A7/fi
Publication of FI970979A0 publication Critical patent/FI970979A0/fi
Publication of FI970979L publication Critical patent/FI970979L/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI970979A 1994-09-08 1995-09-08 Muokatut ihmisen C3-proteiinit FI970979L (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9418147A GB9418147D0 (en) 1994-09-08 1994-09-08 Modified proteins
GBGB9509102.1A GB9509102D0 (en) 1995-05-04 1995-05-04 Modified proteins
PCT/GB1995/002121 WO1996007738A2 (en) 1994-09-08 1995-09-08 Modified human c3 proteins

Publications (3)

Publication Number Publication Date
FI970979A7 true FI970979A7 (fi) 1997-03-07
FI970979A0 FI970979A0 (fi) 1997-03-07
FI970979L FI970979L (fi) 1997-03-07

Family

ID=26305590

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970979A FI970979L (fi) 1994-09-08 1995-09-08 Muokatut ihmisen C3-proteiinit

Country Status (21)

Country Link
US (1) US5849297A (fi)
EP (1) EP0779922B1 (fi)
JP (1) JPH10505241A (fi)
CN (1) CN1104501C (fi)
AT (1) ATE273388T1 (fi)
AU (1) AU707004B2 (fi)
BG (1) BG63606B1 (fi)
BR (1) BR9509172A (fi)
CA (1) CA2197888A1 (fi)
CZ (1) CZ290596B6 (fi)
DE (1) DE69533359T2 (fi)
ES (1) ES2224133T3 (fi)
FI (1) FI970979L (fi)
HU (1) HUT77874A (fi)
NO (1) NO971059L (fi)
NZ (2) NZ333949A (fi)
PL (1) PL319040A1 (fi)
RO (1) RO117189B1 (fi)
RU (1) RU2194713C2 (fi)
SK (1) SK29697A3 (fi)
WO (1) WO1996007738A2 (fi)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000515001A (ja) * 1996-03-07 2000-11-14 イムトラン・リミテッド ダウンレギュレーション耐性c3コンバターゼ
US6221621B1 (en) 1997-03-06 2001-04-24 Bard Diagnostic Sciences, Inc. Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
JP2001515589A (ja) * 1997-03-06 2001-09-18 バイオン ダイアグノスティック サイエンシーズ,インコーポレイテッド 補体レギュレーターまたはレセプタータンパク質を使用するスクリーニングおよび処置
WO2001092295A2 (en) * 2000-05-30 2001-12-06 University Of Toronto Ligands for cd21 and compositions thereof for modulating immune responses
US7294688B2 (en) * 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
US6756476B2 (en) * 2001-04-30 2004-06-29 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
US6998243B2 (en) * 2001-04-30 2006-02-14 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons
US7314717B2 (en) * 2001-04-30 2008-01-01 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
US7179610B2 (en) * 2001-11-23 2007-02-20 Nanogen Inc. Complement C3 precursor biopolymer markers indicative of insulin resistance
US7097989B2 (en) * 2001-11-23 2006-08-29 Syn X Pharma, Inc. Complement C3 precursor biopolymer markers predictive of type II diabetes
RU2251698C1 (ru) * 2003-12-09 2005-05-10 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского Министерства здравоохранения Российской Федерации" СПОСОБ ОПРЕДЕЛЕНИЯ ФУНКЦИОНАЛЬНОЙ АКТИВНОСТИ СУБКОМПОНЕНТОВ C1r2s2 ПЕРВОГО КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА
WO2005107785A2 (en) * 2004-04-30 2005-11-17 University Of Hawaii Human complement c3 derivates with cobra venom factor-like function
US10206998B2 (en) 2005-01-12 2019-02-19 Proteonova, Inc. Modular targeted therapeutic agents and methods of making same
EP3431503A1 (en) * 2005-01-12 2019-01-23 Proteonova, Inc. Method for making targeted therapeutic agents
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
RU2542401C1 (ru) * 2013-11-06 2015-02-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ определения функциональной активности компонента с2 комплемента человека
RU2542404C1 (ru) * 2013-11-06 2015-02-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ определения функциональной активности компонента с4 комплемента человека
US11903996B2 (en) * 2015-10-07 2024-02-20 David C. Fritzinger Modulators of complement function
CN113214373B (zh) * 2020-02-06 2022-08-30 深圳华大基因股份有限公司 新包虫病抗原Murinoglobulin-2蛋白
US11918624B2 (en) * 2020-06-10 2024-03-05 Kelsius Laboratories LLC Therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661347A (en) * 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions

Also Published As

Publication number Publication date
NZ292565A (en) 1999-03-29
NO971059D0 (no) 1997-03-07
NZ333949A (en) 2000-06-23
BR9509172A (pt) 1997-11-25
US5849297A (en) 1998-12-15
MX9701783A (es) 1997-10-31
BG101295A (bg) 1997-12-30
CN1162335A (zh) 1997-10-15
RO117189B1 (ro) 2001-11-30
EP0779922B1 (en) 2004-08-11
WO1996007738A3 (en) 1996-03-28
DE69533359D1 (de) 2004-09-16
CN1104501C (zh) 2003-04-02
CA2197888A1 (en) 1996-03-14
AU3477295A (en) 1996-03-27
ES2224133T3 (es) 2005-03-01
JPH10505241A (ja) 1998-05-26
PL319040A1 (en) 1997-07-21
RU2194713C2 (ru) 2002-12-20
WO1996007738A2 (en) 1996-03-14
NO971059L (no) 1997-05-07
BG63606B1 (bg) 2002-06-28
EP0779922A2 (en) 1997-06-25
AU707004B2 (en) 1999-07-01
CZ68597A3 (en) 1997-11-12
FI970979A0 (fi) 1997-03-07
SK29697A3 (en) 1998-01-14
CZ290596B6 (cs) 2002-08-14
HUT77874A (hu) 1998-09-28
FI970979L (fi) 1997-03-07
ATE273388T1 (de) 2004-08-15
DE69533359T2 (de) 2005-07-28

Similar Documents

Publication Publication Date Title
DE69735996D1 (de) Menschlicher bikunin
BR9509868A (pt) Fralda
DE69634533D1 (de) Wegwerfartikel
DE69501291D1 (de) Ruhesessel
FI970979A7 (fi) Muokatut ihmisen C3-proteiinit
DK0779035T3 (da) Modificeret valleprotein
BR9606951A (pt) Proteinas matantes
DE69837507D1 (de) Humanes Hedgehog-Protein
EP0698666A3 (en) Modified epimorphin
NO951345D0 (no) Stolpesko
TR199701666A3 (tr) Sismanliga karsi proteinler
ATA194094A (de) Artikulator
IT1276074B1 (it) Rettoscopio monouso
IS4520A (is) Einnota peli
ITMI950222A0 (it) Tessuto
DE69503368D1 (de) Dermatologisches präparat
DE69523817D1 (de) Desodorisierende Präparate
DE69434900D1 (de) Menschliche chemokin-polypeptide
KR960006934U (ko) 의자
ATA155395A (de) Funktionelle lumbalbandage
KR960009822U (ko) 의자
KR960006928U (ko) 위치변형 가능한 의자
SE9701041D0 (sv) Novel proteins and their use
SE9602287D0 (sv) Novel protein and methods for its use
PT101483A (pt) Instrumento cirurgico - porta/passa - fios